These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 27005457)

  • 1. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.
    Syue LS; Chen YH; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2016 Apr; 47(4):250-8. PubMed ID: 27005457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antimicrobial options for the management of complicated intra-abdominal infections.
    Leone S; Damiani G; Pezone I; Kelly ME; Cascella M; Alfieri A; Pace MC; Fiore M
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):819-827. PubMed ID: 30903538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.
    Lin SY; Huang CH; Ko WC; Chen YH; Hsueh PR
    Expert Opin Pharmacother; 2016; 17(3):339-54. PubMed ID: 26610040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.
    Lee YR; McMahan D; McCall C; Perry GK
    Drugs; 2015 Dec; 75(18):2097-117. PubMed ID: 26612473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Challenge of Antimicrobial Resistance in Managing Intra-Abdominal Infections.
    Sartelli M; Catena F; di Saverio S; Ansaloni L; Coccolini F; Tranà C; Kirkby-Bott J
    Surg Infect (Larchmt); 2015 Jun; 16(3):213-20. PubMed ID: 25831090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
    Wright H; Bonomo RA; Paterson DL
    Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C; Solomkin J
    Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eravacycline for the treatment of intra-abdominal infections.
    Bassetti M; Righi E
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1575-84. PubMed ID: 25251475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Mawal Y; Critchley IA; Riccobene TA; Talley AK
    Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
    Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials.
    Chen TY; Hsu CK; Shih SC; Weng TS; Tang HJ; Lai CC
    Int J Antimicrob Agents; 2023 Aug; 62(2):106844. PubMed ID: 37160243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
    Buckman SA; Krekel T; Muller AE; Mazuski JE
    Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.